Grail, Inc. revenue
Grail, Inc.'s revenue was $147m in fiscal 2025, up 17.2% on the year before. Since fiscal 2022 ($55.5m) it has grown at a compound 38.4% a year. Over the last twelve months it was $165m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Screening Revenue | $139M | 94.2% | ▲ 27.6% |
| Developmental Services Revenue | $8.6M | 5.8% | ▼ 49.5% |
From Grail, Inc.'s 10-K filed March 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Grail, Inc. | $165m | 23.1% | — |
| Pacific Biosciences Of California, Inc. | $159m | 2.0% | 2.9% |
| Quanterix Corp | $153m | 22.0% | 11.1% |
| Cryoport, Inc. | $186m | 12.1% | -8.2% |
| Cytek Biosciences, Inc. | $207m | 5.4% | 5.6% |
| Maravai Lifesciences Holdings, Inc. | $209m | -5.0% | -27.3% |
Compare with peers
- Pacific Biosciences Of California, Inc. revenue
- Quanterix Corp revenue
- Cryoport, Inc. revenue
- Cytek Biosciences, Inc. revenue
- Maravai Lifesciences Holdings, Inc. revenue
Head to head: GRAL vs PACBGRAL vs QTRXCYRX vs GRAL
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies